Gene Therapy Developer Faces Regulatory Crisis as Clinical Trials Halted
Intellia Therapeutics, a prominent gene-editing company, is confronting a severe setback after U.S. regulators imposed a clinical hold on two crucial Phase 3 studies. The…


